Thus, among the generally favourable group of initially TP53 wild-type ALK+ tumours, acquisition of TP53 mutations identifies an unfavourable subgroup with a clinical course similar to that of primarily TP53 mutated cases. The gene discussed is TP53; the disease is neoplasm.